Renalytix Plc (LON:RENX – Get Free Report) dropped 1.7% on Monday . The stock traded as low as GBX 5.80 and last traded at GBX 5.80. Approximately 561,166 shares were traded during trading, a decline of 62% from the average daily volume of 1,471,433 shares. The stock had previously closed at GBX 5.90.
Renalytix Stock Performance
The company’s fifty day moving average price is GBX 6.94 and its two-hundred day moving average price is GBX 7.21. The company has a debt-to-equity ratio of -72.91, a quick ratio of 2.42 and a current ratio of 0.24. The firm has a market capitalization of £25.35 million, a PE ratio of -0.83 and a beta of 2.10.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Stories
- Five stocks we like better than Renalytix
- Wall Street Stockpicker Names #1 Stock of 2026
- Trump’s new AI budget just passed — one stock could soar
- [How To] Claim Your Pre-IPO Stake In SpaceX!
- Drop these 5 stocks now!
- The McDonald’s Secret
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
